Sökning: onr:"swepub:oai:DiVA.org:uu-393496" >
Clinical impact of ...
Clinical impact of antithrombotic therapy in transvenous lead extraction complications : a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTRolled) Registry
-
Di Cori, Andrea (författare)
-
Auricchio, Angelo (författare)
-
Regoli, François (författare)
-
visa fler...
-
- Blomström-Lundqvist, Carina (författare)
- Uppsala universitet,Kardiologi-arrytmi,Kardiologi
-
Butter, Christian (författare)
-
Dagres, Nikolaos (författare)
-
Deharo, Jean-Claude (författare)
-
Maggioni, Aldo P (författare)
-
Kutarski, Andrzej (författare)
-
Kennergren, Charles (författare)
-
Laroche, Cécile (författare)
-
Rinaldi, Christopher A (författare)
-
Dovellini, Emilio Vincenzo (författare)
-
Golzio, Pier Giorgio (författare)
-
Thøgersen, Anna Margrethe (författare)
-
Bongiorni, Maria Grazia (författare)
-
visa färre...
-
(creator_code:org_t)
- 2019-04-10
- 2019
- Engelska.
-
Ingår i: Europace. - : Oxford University Press. - 1099-5129 .- 1532-2092. ; 21:7, s. 1096-1105
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIMS: A sub-analysis of the ESC-EHRA European Lead Extraction ConTRolled (ELECTRa) Registry to evaluate the clinical impact of antithrombotic (AT) on transvenous lead extraction (TLE) safety and efficacy.METHODS AND RESULTS: ELECTRa outcomes were compared between patients without AT therapy (No AT Group) and with different pre-operative AT regimens, including antiplatelets (AP), anticoagulants (AC), or both (AP + AC). Out of 3510 pts, 2398 (68%) were under AT pre-operatively. AT patients were older with more comorbidities (P < 0.0001). AT subgroups, defined as AP, AC, or AP + AC, were 1096 (31.2%), 985 (28%), and 317 (9%), respectively. Regarding AP patients, 1413 (40%) were under AP, 1292 (91%) with a single AP, interrupted in 26% about 3.8 ± 3.7 days before TLE. In total, 1302 (37%) patients were under AC, 881 vitamin K antagonist (68%), 221 (17%) direct oral anticoagulants, 155 (12%) low weight molecular heparin, and 45 (3.5%) unfractionated heparin. AC was 'interrupted without bridging' in 696 (54%) and 'interrupted with bridging' in 504 (39%) about 3.3 ± 2.3 days before TLE, and 'continued' in 87 (7%). TLE success rate was high in all subgroups. Only overall in-hospital death (1.4%), but not the procedure-related one, was higher in the AT subgroups (P = 0.0500). Age >65 years and New York Heart Association Class III/IV, but not AT regimens, were independent predictors of death for any cause. Haematomas were more frequent in AT subgroups, especially in AC 'continued' (P = 0.025), whereas pulmonary embolism in the No-AT (P < 0.01).CONCLUSIONS: AT minimization is safe in patients undergoing TLE. AT does not seem to predict death but identifies a subset of fragile patients with a worse in-hospital TLE outcome.
Nyckelord
- Antithrombotic therapy
- ELECTRa Registry
- Transvenous lead extraction
- Cardiology
- Kardiologi
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Europace
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Di Cori, Andrea
-
Auricchio, Angel ...
-
Regoli, François
-
Blomström-Lundqv ...
-
Butter, Christia ...
-
Dagres, Nikolaos
-
visa fler...
-
Deharo, Jean-Cla ...
-
Maggioni, Aldo P
-
Kutarski, Andrze ...
-
Kennergren, Char ...
-
Laroche, Cécile
-
Rinaldi, Christo ...
-
Dovellini, Emili ...
-
Golzio, Pier Gio ...
-
Thøgersen, Anna ...
-
Bongiorni, Maria ...
-
visa färre...
- Artiklar i publikationen
-
Europace
- Av lärosätet
-
Uppsala universitet